中国血液透析患者肌少症诊断列线图的开发与验证
研究基于中国上海和苏州7个血液透析中心的757例患者横断面数据,构建并验证仅含年龄、性别、体重和握力4个变量的肌少症诊断列线图。训练集C指数0.929,外部验证集0.955, cutoff值0.725时灵敏度0.909、特异度0.816。列线图对血液透析患者肌少症诊断能力良好,可能便于临床使用。
要点
- 基于4个变量(年龄、性别、体重、握力)的列线图诊断血液透析患者肌少症。
- 训练集C指数0.929(95%CI 0.904-0.953),外部验证集0.955(95%CI 0.931-0.979)。
- cutoff值0.725,灵敏度0.909,特异度0.816。
核心结论
- 列线图对血液透析患者肌少症具有良好的诊断能力,可能成为临床使用的便捷工具。
研究设计与样本
- 横断面研究,纳入2020至2021年中国上海和苏州7个血液透析中心的757例合格患者。
- 训练集为来自5个中心的511例连续患者(肌少症77例,无肌少症434例),用于建立诊断列线图。
- 验证集为246例连续患者(肌少症47例,无肌少症199例),用于验证诊断模型。
- 肌少症诊断依据亚洲肌少症工作组2019标准。
主要发现
- 入组患者平均年龄60.4±12.1岁,男性占59.8%,90.5%使用动静脉内瘘透析。
- 总体肌少症发生率为16.4%;训练集与验证集肌少症发生率分别为15.1%和19.1%,两组无显著差异(P=0.160)。
- 基于年龄、性别、体重和握力4个特征的列线图在训练集和外部验证集的C指数分别为0.929(95%CI 0.904-0.953)和0.955(95%CI 0.931-0.979),校准曲线拟合良好。
- cutoff值为0.725,灵敏度0.909,特异度0.816。
关键数值与推荐
- 肌少症诊断采用亚洲肌少症工作组2019标准。
- 列线图cutoff值0.725,灵敏度0.909,特异度0.816。
临床怎么用
- 原文结论认为列线图可能成为临床使用的便捷工具。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sarcopenia is a clinical condition that is common in patients with chronic kidney disease (CKD), especially in those on dialysis. However, the relatively complicated diagnostic procedure limits its use in clinical situations. In this study we aimed to establish a simplified tool for the diagnosis of sarcopenia in patients on hemodialysis (HD). METHODS: Overall, 757 eligible patients from seven HD centers in Shanghai and Suzhou, China, were recruited from 2020 to 2021. The cross-sectional data were analyzed. Sarcopenia was diagnosed according to the Asian Working Group for Sarcopenia 2019 criteria. Among them, 511 consecutive patients (77 with and 434 without sarcopenia) from five centers were included in the training set for the establishment of a diagnostic nomogram. Ten investigative parameters including clinical characteristics, body measurements and physical performance were used to derive the diagnostic nomogram. A total of 246 consecutive patients (47 with and 199 without sarcopenia) were included for validation of the diagnostic model. RESULTS: The average age of the enrolled patients was 60.4 ± 12.1 years, 59.8% were males and 90.5% received dialysis using an arteriovenous fistula. Overall, the sarcopenia rate was 16.4%. The training and validation sets showed no significant differences in sarcopenia rate (15.1% and 19.1%, respectively; P = .160). The nomogram derived from the training set for sarcopenia, which was based on only four features-age, sex, body weight and grip strength-achieved high C-indexes of 0.929 [95% confidence interval (CI) 0.904-0.953] and 0.955 (95% CI 0.931-0.979) in the training and external sets, respectively, and had a well-fitted calibration curve. The cut-off value was 0.725, with a sensitivity of 0.909 and a specificity of 0.816. The nomogram accurately diagnosed sarcopenia with fewer variables and more simplified diagnostic procedures. CONCLUSIONS: The nomogram had a good diagnostic capability for sarcopenia in patients on HD and may be a convenient tool for clinical use.
引用
- Xie D, Zhu Q, Lu J, et al. Development and validation of a diagnostic nomogram for sarcopenia in Chinese hemodialysis patients. Nephrol Dial Transplant. 2023. PMID: 36084001. doi:10.1093/ndt/gfac260
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。